Discover 3,059 paid clinical trials in Brockton, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
for
Diabetes Mellitus, Type 2
Location: Boston MA, Columbus OH, Stanford CA
Sponsor: Stanford University
Sex: All
Age: 18+
Code: NCT06251323
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
for
Locally Advanced Head and Neck Squamous Cell Carcinoma
Location: Boston MA, Fairhaven MA, Stony Brook NY, New York NY,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06129864
Phase 3, Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
for
Non-small Cell Lung Cancer,
Location: Boston MA, New York NY, New Brunswick NJ, Pittsburgh PA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05877599
Phase 1, Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
for
Metastatic Castration-Resistant Prostate Cancer
Location: Boston MA, Chicago IL, Tampa FL, Miami FL, Omaha NE
Sponsor: AstraZeneca
Sex: Male
Age: 18+
Code: NCT06879041
Phase 1, Recruiting
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
for
Clear Cell Renal Cell Carcinoma, Solid Tumors
Location: Boston MA, New York NY, Baltimore MD, Pittsburgh PA,
Sponsor: Arcus Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT05536141
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
for
Relapsed/Refractory Multiple Myeloma
Location: Boston MA, Stony Brook NY, New York NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05850234
Phase 1, Phase 2, Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
for
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma,
Location: Boston MA, Providence RI, New York NY, Hackensack NJ,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06564038
Phase 1, Phase 2, Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, Montreal, Baltimore MD,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT05061550
Phase 2, Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
for
Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma,
Location: Boston MA, New York NY, Philadelphia PA, Miami FL,
Sponsor: AstraZeneca
Sex: All
Age: 12+
Code: NCT06137144
Phase 1, Phase 2, Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
for
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer,
Location: Boston MA, Commack NY, Ottawa, Baltimore MD, Toronto,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05123482
Phase 1, Phase 2, Recruiting
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
for
Chronic Lymphocytic Leukemia (CLL),
Location: Boston MA, Durham NC, Winston-Salem NC, Charlotte NC
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT07024706
Phase 2, Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
for
Non-small Cell Lung Cancer (NSCLC)
Location: Boston MA, South Portland ME, East Syracuse NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07291037
Phase 3, Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
for
Metastatic Clear Cell Renal Cell Carcinoma,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Arcus Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT07011719
Phase 3, Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
for
Relapsed AL Amyloidosis, Refractory AL Amyloidosis,
Location: Boston MA, New York NY, Toronto, Cleveland OH,
Sponsor: Alexion Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07081646
Phase 1, Phase 2, Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
for
Advanced Breast Cancer
Location: Boston MA, Stony Brook NY, Mineola NY, New York NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06380751
Phase 3, Recruiting
Observational Study Protocol: LIVER-R
for
Hepatobiliary Cancers
Location: Boston MA, White Plains NY, Bethlehem PA,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06252753
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for
Non-Small Cell Lung Cancer
Location: Boston MA, Stony Brook NY, Montreal, Trois-Rivieres,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06357533
Phase 3, Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
for
Multiple Myeloma
Location: Boston MA, New York NY, Philadelphia PA, Montreal,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06106945
Phase 1, Phase 2, Recruiting
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
for
Advanced Solid Malignancies
Location: Boston MA, New York NY, Chicago IL, Houston TX,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT05417594
Phase 1, Phase 2, Recruiting
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy